期刊
CURRENT PHARMACEUTICAL DESIGN
卷 19, 期 4, 页码 578-613出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161213804581918
关键词
Epigenetics; anticancer therapy; DNA methyltransferases; protein methyltransferases; demethylases; deacetylases; acetyltransferases; histone post-translational modifications; drug design; crystallography; small-molecule inhibitors
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC) - Emilia Romagna Start-Up grant [6266]
Research on cancer epigenetics has flourished in the last decade. Nevertheless growing evidence point on the importance to understand the mechanisms by which epigenetic changes regulate the genesis and progression of cancer growth. Several epigenetic targets have been discovered and are currently under validation for new anticancer therapies. Drug discovery approaches aiming to target these epigenetic enzymes with small-molecules inhibitors have produced the first pre-clinical and clinical outcomes and many other compounds are now entering the pipeline as new candidate epidrugs. The most studied targets can be ascribed to histone deacetylases and DNA methyltransferases, although several other classes of enzymes are able to operate post-translational modifications to histone tails are also likely to represent new frontiers for therapeutic interventions. By acknowledging that the field of cancer epigenetics is evolving with an impressive rate of new findings, with this review we aim to provide a current overview of pre-clinical applications of small-molecules for cancer pathologies, combining them with the current knowledge of epigenetic targets in terms of available structural data and drug design perspectives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据